Exosomes from embryonic mesenchymal stem cells alleviate osteoarthritis through balancing synthesis and degradation of cartilage extracellular matrix.

Wang Y, Yu D, Liu Z, Zhou F, Dai J, Wu B, Zhou J, Heng BC, Zou XH, Ouyang H, Liu H. · 2017

Read Exosomes from embryonic mesenchymal stem cells alleviate osteoarthritis through balancing synthesis and degradation of cartilage extracellular matrix. by Wang Y, Yu D, Liu Z, Zhou F, Dai J, Wu B, Zhou J, Heng BC, Zou XH, Ouyang H, Liu H. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5556343.txt.

Introduction

Wang and co-authors present a research article in Stem Cell Research & Therapy. Their subject is osteoarthritis, a joint disease that wears down cartilage. Stem cell treatment has shown promise, but the reason was unclear. The team tests whether tiny vesicles from the cells do the work.

The stem cells came from human embryonic stem cells. In mice with a knee injury model, injections of the cells eased cartilage damage. Lab tests then showed the effect came from their exosomes. Those vesicles raised collagen output and lowered a matrix-cutting enzyme in cartilage cells. Injections of exosomes alone also protected mouse cartilage. Readers see a possible cell-free path for joint treatment.

Catalog record

CREATORWang Y, Yu D, Liu Z, Zhou F, Dai J, Wu B, Zhou J, Heng BC, Zou XH, Ouyang H, Liu H.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE55 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5556343

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Exosomes from embryonic mesenchymal stem cells alleviate osteoarthritis through balancing synthesis and degradation of cartilage extracellular matrix By Yafei Wang, Dongsheng Yu, Zhiming Liu, Fang Zhou, Jun Dai, Bingbing Wu, Jing Zhou, Boon Chin Heng, Xiao Hui Zou, Hongwei Ouyang, Hua Liu Published in: Stem Cell Research & Therapy DOI: 10.1186/s13287-017-0632-0 ABSTRACT Abstract Background Mesenchymal stem cell therapy for osteoarthritis (OA) has been widely investigated, but the mechanisms are still unclear. Exosomes that serve as carriers of genetic information have been implicated in many diseases and are known to participate in many physiological processes. Here, we investigate the therapeutic potential of exosomes from human embryonic stem cell-induced mesenchymal stem cells (ESC-MSCs) in alleviating osteoarthritis (OA). Methods Exosomes were harvested from conditioned culture media of ESC-MSCs by a sequential centrifugation process. Primary mouse chondrocytes treated with interleukin 1 beta (IL-1β) were used as an in vitro model to evaluate the effects of the conditioned medium with or without exosomes and titrated doses of isolated exosomes for 48 hours, prior to immunocytochemistry or western blot analysis. Destabilization of the medial meniscus (DMM) surgery was performed on the knee joints of C57BL/6 J mice as an OA model. This was followed by intra-articular injection of either ESC-MSCs or their exosomes. Cartilage destruction and matrix degradation were evaluated with histological staining and OARSI scores at the post-surgery 8 weeks. Results We found that intra-articular injection of ESC-MSCs alleviated cartilage destruction and matrix degradation in the DMM model. Further in vitro studies illustrated that this effect was exerted through ESC-MSC-derived exosomes. These exosomes maintained the chondrocyte phenotype by increasing collagen type II synthesis and decreasing ADAMTS5 expression in the presence of IL-1β. Immunocytochemistry revealed colocalization of the exosomes and collagen type II-positive chondrocytes. Subsequent intra-articular injection of exosomes derived from ESC-MSCs successfully impeded cartilage destruction in the DMM model. Conclusions The exosomes from ESC-MSCs exert a beneficial therapeutic effect on OA by balancing the synthesis and degradation of chondrocyte extracellular matrix (ECM), which in turn provides a new target for OA drug and drug-delivery system development. Electronic supplementary material The online version of this article (doi:10.1186/s13287-017-0632-0) contains supplementary material, which is available to authorized users. Keywords: ESC, MSCs, Exosomes, Osteoarthritis BACKGROUND Osteoarthritis (OA) is a common joint disease worldwide, which exerts a significant detrimental effect on the patients’ life quality [1]. Pharmaceutical agents, particularly nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol, have been widely applied in the clinic. However, their effects are largely limited to pain control with negligible effects on cartilage maintenance, which would ultimately lead to cartilage destruction [2, 3]. Although surgical interventions such as total knee or hip arthroplasty could partially overcome pain and deformity in end-stage OA patients, this could also cause further complications such as increased risks of infection, thrombus formation and secondary surgery, particularly in elderly patients [4–6]. Hence, there is a dire need to develop new strategies to protect cartilage and attenuate OA development, particularly minimally invasive interventions at the early stages of OA. Cell transplantation is an emerging therapeutic modality for OA treatment, and mainly involves the utilization of autologous chondrocytes and mesenchymal stem cells [7, 8]. Although autologous chondrocytes as the main cell type in cartilage may provide a safe and efficacious solution, these have the inherent drawbacks of limited availability, de-differentiation and function loss during the process of in vitro expansion [8]. Therefore, the application of mesenchymal stem cells (MSCs) for OA therapy has attracted much more attention from scientific investigators [7, 9–11]. Clinical applications of adult MSCs are limited by donor source and individual physical conditions [12–14]. MSCs derived from pluripotent embryonic stem cells (ESC-MSCs) have become another potential and promising source of MSCs. The unlimited self-renewal capacity and pluripotency of ESCs [15] in turn ensures less inter-batch variability and a more consistent supply of ESC-MSCs. Furthermore, as a cell source for the treatment of various diseases, ESC-MSCs have also been reported to possess immunomodulatory properties, as well as regenerative potential, similar to adult MSCs [16]. However, there have not yet been any studies that have investigated their therapeutic effects on OA and probed the underlying mechanisms involved. Besides the well-documented immunomodulatory properties and multidifferentiation capacity of MSCs [16–18], the communication and interaction between MSCs and chondrocytes, either by direct cell-cell contact or indirectly via secretions such as exosomes, have aroused much interest [11, 19–22]. As one of the major pathways of extracellular signaling, exosomes have been implicated in many diseases and participate in many physiological processes. These are derived from fusion in cell to cell communication, as well as serve as carriers of genetic information [23]. Recently, exosomes derived from MSCs have received much attention due to a study showing that severe graft versus host disease (GVHD) can be treated with MSCs-derived extracellular vesicles [24], thus suggesting that the observed therapeutic effects of MSCs can in fact be reproduced by MSCs-derived exosome treatment [19, 25]. In this study, we report the positive therapeutic effects of ESC-MSCs on osteoarthritis, and investigate the underlying mechanisms involved. METHODS Mice and OA model Thirty-two 2-month-old C57BL/6 J mice purchased from the animal center of Zhejiang University were utilized for all experiments. The mice were anesthetized with sodium pentobarbital (8 mg/ml, 1 ml/100 g) and randomly distributed into experimental and control groups. Among them, 12 mice were in the sham group, and 20 mice were utilized for the experimental OA model, which was induced by destabilization of the medial meniscus (DMM) surgery, following the transection of the medial meniscotibial ligament as previously described [26]. In the first animal section, DMM surgery was performed in the bilateral knee joints and five mice were allocated to each group. Three mice were allocated to each sham group. OA pathology developed gradually throughout 4 weeks before single intra-articular injection of 5 μL ESC-MSCs (1 × 106/joint) or 5 μL PBS per joint with a microliter syringe (Hamilton Company, Reno, NV, USA, 1702) and 5 mm 30-gauge needles (Hamilton Company, 7803-05). In the second animal section, DMM surgery was performed in the bilateral knee joints and five mice were allocated to each group. Three mice were allocated to each sham group. OA pathology developed gradually throughout 4 weeks before multiple injections of 5 μL exosomes isolated from ESC-MSCs per joint or 5 μL PBS per joint, which was performed every 3 days for 4 weeks with a microliter syringe (Hamilton Company, 1702) and 5 mm 30-gauge needles (Hamilton Company, 7803-05). Cell culture MSCs were derived from the male H1 human ES cell line (ESC) that was obtained from WiCell Corporation. Madison, WI, USA (http://www.wicell.org), which was maintained in the undifferentiated state by culture in a feeder-free system. ESC-MSCs were obtained as described in our previous study [27]. Briefly, ESCs were detached from Matrigel (BD, Franklin Lakes, NJ, USA, Cat. #354234) coated plates by a 10-minute (min) incubation with 0.02% (w/v) EDTA (Sigma-Aldrich, St. Louis, MO, USA, Cat. #E8008) and seeded onto a gelatinized 10-cm plates. The cells were cultured in L-DMEM (Life Technologies, Carlsbad, CA, USA, Cat. #11885084) supplemented with 10% (v/v) fetal bovine serum (FBS; Life Technologies, Cat. #10099-141). The cells were then trypsinized (0.05% (w/v), Life Technologies, Cat. #15400-054) upon reaching 80% confluency and then plated at a density of 103 cells/cm2.

Read the complete text